| DB ID | MyCo_2765 |
| Title | Investigation of the value of precipitins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with a positive marker for Aspergillus species |
| Year | 2022 |
| PMID | 35604675 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | COVID-19 |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | In total, 225 SARS-CoV-2 ICU patients were managed between March 2020 and December 2020 at the ICU of the Univer- sity Hospital of Besancon. During both the first COVID-19 wave in France (March 2020-May 2020), and the second one 2020), 16/135 and 19/90 SARS-CoV-2 ICU patients presented a positive marker for Aspergillus species detection during their ICU stay (either a positive culture in tracheal aspirate, a positive culture in BAL, a positive galactomannan in serum, or a posi- tive A. fumigatus qPCR in serum). Overall, 35 SARS-CoV-2 ICU patients (35/225; 15.5%) were included retrospectively in the “A. fumigatus group”. Thirty SARS-CoV-2 ICU patients were randomly chosen among the 185 patients with no positive marker for Aspergillus species detection during their ICU stay (30/225; 13.3%) to be included in the “control group”. (October 2020-December |
| Cohort No. | 65 Patients |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA-qPCR Based |
| ELISA kits | PolySorp Immunomodule ®, Nalge Nunc, Rochester, NY |
| Assay Data | None |
| Validation Techniques used | ELISA, qPCR |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
